Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

An asthma drug has shown positive results when used to treat nasal polyps, researchers have said. Tezepelumab was first ...

Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a ...

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

Amgen and AstraZeneca have announced full results from the Phase III, registrational WAYPOINT trial showing that Tezspire ...

Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire ...

A global drug trial to test the effectiveness of the asthma drug tezepelumab in treating nasal polyps has shown significant ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...